Surrozen (SRZN) Cash from Financing Activities (2020 - 2026)
Surrozen (SRZN) posted quarterly Cash from Financing Activities of $30.3 million for Q1 2026, down 60.36% year-over-year from $76.4 million in Q1 2025, and up 119.72% quarter-over-quarter from $13.8 million in Q4 2025.
Surrozen (SRZN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Surrozen's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $30.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 60.36% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $38.9 million (down 57.92% YoY), while the FY2025 annual figure was $85.1 million, up 425.79% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $30.3 million, up from $13.8 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $76.4 million in Q1 2025, with the low at -$5.1 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is $9000.0 (2025), against an average of $8.6 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 1703.14% in 2022, then soared 15043.96% in 2025.
- Surrozen's Cash from Financing Activities stood at -$2.5 million in 2022, then jumped by 105.53% to $141000.0 in 2023, then sank by 35.46% to $91000.0 in 2024, then jumped by 15043.96% to $13.8 million in 2025, then surged by 119.72% to $30.3 million in 2026.
- Business Quant data shows SRZN's Cash from Financing Activities at $30.3 million in Q1 2026, $13.8 million in Q4 2025, and $9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.51 Mn |
| Jun 30, 2026 | 2.51 Mn |
| Mar 31, 2026 | 30.28 Mn |
| Mar 31, 2026 | 30.28 Mn |
| Dec 31, 2025 | 13.78 Mn |
| Dec 31, 2025 | 13.78 Mn |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 16.09 Mn |
| Jun 30, 2024 | 16.09 Mn |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |